Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Transpl Infect Dis ; 23(3): e13520, 2021 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-33222379

RESUMO

BACKGROUND: Whether active therapy with ß-lactam/ß-lactamase inhibitors (BLBLI) is as affective as carbapenems for extended-spectrum ß-lactamase-producing Enterobacterales (ESBL-E) bloodstream infection (BSI) secondary to urinary tract infection (UTI) in kidney transplant recipients (KTRs) remains unclear. METHODS: We retrospectively evaluated 306 KTR admitted to 30 centers from January 2014 to October 2016. Therapeutic failure (lack of cure or clinical improvement and/or death from any cause) at days 7 and 30 from ESBL-E BSI onset was the primary and secondary study outcomes, respectively. RESULTS: Therapeutic failure at days 7 and 30 occurred in 8.2% (25/306) and 13.4% (41/306) of patients. Hospital-acquired BSI (adjusted OR [aOR]: 4.10; 95% confidence interval [CI]: 1.50-11.20) and Pitt score (aOR: 1.47; 95% CI: 1.21-1.77) were independently associated with therapeutic failure at day 7. Age-adjusted Charlson Index (aOR: 1.25; 95% CI: 1.05-1.48), Pitt score (aOR: 1.72; 95% CI: 1.35-2.17), and lymphocyte count ≤500 cells/µL at presentation (aOR: 3.16; 95% CI: 1.42-7.06) predicted therapeutic failure at day 30. Carbapenem monotherapy (68.6%, primarily meropenem) was the most frequent active therapy, followed by BLBLI monotherapy (10.8%, mostly piperacillin-tazobactam). Propensity score (PS)-adjusted models revealed no significant impact of the choice of active therapy (carbapenem-containing vs any other regimen, BLBLI- vs carbapenem-based monotherapy) within the first 72 hours on any of the study outcomes. CONCLUSIONS: Our data suggest that active therapy based on BLBLI may be as effective as carbapenem-containing regimens for ESBL-E BSI secondary to UTI in the specific population of KTR. Potential residual confounding and unpowered sample size cannot be excluded (ClinicalTrials.gov identifier: NCT02852902).


Assuntos
Bacteriemia , Transplante de Rim , Infecções Urinárias , Antibacterianos/uso terapêutico , Bacteriemia/tratamento farmacológico , Carbapenêmicos , Infecções por Enterobacteriaceae/tratamento farmacológico , Humanos , Lactamas , Estudos Retrospectivos , Infecções Urinárias/tratamento farmacológico , Inibidores de beta-Lactamases/uso terapêutico , beta-Lactamases
2.
Travel Med Infect Dis ; 25: 31-34, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29680285

RESUMO

INTRODUCTION: In non-endemic countries, one of the most important routes of transmission of Trypanosoma cruzi is vertical transmission. The objective of this work is to report the results of the screening activities for the control of congenital Chagas Disease (CD) implemented in Bergamo province between January 2014 and December 2016. METHODS: The programme addressed Bolivian pregnant women settled in Bergamo province. All the eight hospitals offering antenatal and delivery care in that area were involved. We retrospectively calculated the coverage rate of the screening programme, the prevalence of CD in this population, as well as transmission rate to their offspring. RESULTS: During the study period, 376 Bolivian women accounted for 387 deliveries. The coverage rate of serologic screening was 85.6%. Confirmed seropositive women were 28, accounting for a prevalence of CD of 8.7% (95% IC 5.9-11.5). Among 29 children born to positive mothers, one infected child was detected (transmission rate of 4.3%, 95% IC 0-12.6) and treated accordingly. Other 13 children previously born from the same mothers were retrieved and tested for CD: no additional congenital cases were diagnosed. DISCUSSION: Our screening programme presented a high coverage, although widely variable in the different birthing facilities. National guidelines recommending CD testing in pregnant women would help to increase case detection countrywide.


Assuntos
Doença de Chagas/epidemiologia , Doença de Chagas/prevenção & controle , Controle de Doenças Transmissíveis/métodos , Bolívia , Doença de Chagas/tratamento farmacológico , Feminino , Humanos , Recém-Nascido , Itália , Masculino , Nitroimidazóis/uso terapêutico , Gravidez , Complicações Parasitárias na Gravidez/epidemiologia , Fatores de Risco , Tripanossomicidas/uso terapêutico , Trypanosoma cruzi
3.
Rev Iberoam Micol ; 22(3): 169-71, 2005 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16309355

RESUMO

In the past the Italian soil was considered as a low-endemic pabulum for H. capsulatum var. capsulatum and only few autochthonous cases of histoplasmosis were reported in Italy, especially in the Po valley. The aim of the paper was to evaluate this possibility by reviewing the literature and providing our own personal data. Four additional cases of histoplasmosis were observed during 1999-2003 in AIDS immigrant or in Italian citizens, and in travellers to endemic areas. One of the AIDS patients was an autochthonous case of histoplasmosis. The Italian literature was reviewed. Recent cases and literature data confirm the possible autochthonous presence of histoplasmosis in Italy, especially in the Northern regions.


Assuntos
Histoplasmose/epidemiologia , Infecções Oportunistas Relacionadas com a AIDS/epidemiologia , Infecções Oportunistas Relacionadas com a AIDS/microbiologia , Adulto , Côte d'Ivoire/etnologia , Emigração e Imigração , Feminino , Humanos , Itália/epidemiologia , América Latina , Masculino , Pessoa de Meia-Idade , Nicarágua , Paquistão , Estudos Retrospectivos , Tanzânia , Viagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA